AEGIRBIO Receives Milestone Payment under RadX NIH - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Analys: Står sig Nordnet och Avanza i allt hårdare konkurrens? / Storbankens nya prognos: Styrräntan behöver sänkas till 1,5 procent

Pressmeddelande

AEGIRBIO Receives Milestone Payment under RadX NIH

Cision Publicerad: 08 May 09:00
Magnasense

AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the company has received its inaugural milestone-based payment of USD 148,026 under the RadX NIH program. This milestone validates our unwavering dedication to pioneering research and development.

"At AegirBio, we are committed to pushing the boundaries of innovation and fostering positive change in healthcare. This payment from RadX NIH reflects the tireless efforts of our team," said Marco Witteveen, CEO of AegirBio.

As we celebrate this milestone, our commitment to advancing with RadX remains unwavering. With ongoing support from initiatives like RadX NIH and the expertise of our talented team, we are positioned to drive significant progress and make meaningful contributions to the field.

Nyheter om Magnasense

Läses av andra just nu

Om aktien Magnasense

Senaste nytt